617 related articles for article (PubMed ID: 24766397)
1. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Verpeut JL; Bello NT
Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
[TBL] [Abstract][Full Text] [Related]
2. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
Padwal R
Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
[TBL] [Abstract][Full Text] [Related]
3. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Halpern B; Mancini MC
Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
[TBL] [Abstract][Full Text] [Related]
4. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
Ali KF; Shukla AP; Aronne LJ
Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
[TBL] [Abstract][Full Text] [Related]
6. Contrave--a combination of bupropion and naltrexone for weight loss.
Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
[No Abstract] [Full Text] [Related]
7. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with naltrexone and bupropion for obesity.
Billes SK; Greenway FL
Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
[TBL] [Abstract][Full Text] [Related]
10. ACS chemical neuroscience molecule spotlight on contrave.
Mercer SL
ACS Chem Neurosci; 2011 Sep; 2(9):484-6. PubMed ID: 22860172
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.
Prescrire Int; 2015 Oct; 24(164):229-33. PubMed ID: 26594724
[TBL] [Abstract][Full Text] [Related]
12. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
[TBL] [Abstract][Full Text] [Related]
13. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
14. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
Apovian CM
Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
[TBL] [Abstract][Full Text] [Related]
15. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
[TBL] [Abstract][Full Text] [Related]
16. Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Bello NT
Expert Opin Drug Saf; 2019 Jul; 18(7):549-552. PubMed ID: 31092063
[No Abstract] [Full Text] [Related]
17. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
Greig SL; Keating GM
Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ; Lee SY
Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
[TBL] [Abstract][Full Text] [Related]
19. Comparison table: some FDA-approved drugs for weight management.
Med Lett Drugs Ther; 2018 Jun; 60(1548):e98-e100. PubMed ID: 29913464
[No Abstract] [Full Text] [Related]
20. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
Khalil H; Ellwood L; Lord H; Fernandez R
Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
[No Abstract] [Full Text] [Related]
[Next] [New Search]
